These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20514488)

  • 21. Ataxin-1 fusion partners alter polyQ lethality and aggregation.
    Rich T; Varadaraj A
    PLoS One; 2007 Oct; 2(10):e1014. PubMed ID: 17925862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo.
    Beam M; Silva MC; Morimoto RI
    J Biol Chem; 2012 Jul; 287(31):26136-45. PubMed ID: 22669943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyglutamine aggregation in Huntington and related diseases.
    Polling S; Hill AF; Hatters DM
    Adv Exp Med Biol; 2012; 769():125-40. PubMed ID: 23560308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
    Wetzel R
    Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular Pathogenesis of Polyglutamine Diseases].
    Takahashi Y
    Brain Nerve; 2017 Aug; 69(8):901-912. PubMed ID: 28819074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D-polyglutamine amyloid recruits L-polyglutamine monomers and kills cells.
    Kar K; Arduini I; Drombosky KW; van der Wel PC; Wetzel R
    J Mol Biol; 2014 Feb; 426(4):816-29. PubMed ID: 24291210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanin attenuates apoptosis induced by DRPLA proteins with expanded polyglutamine stretches.
    Kariya S; Hirano M; Nagai Y; Furiya Y; Fujikake N; Toda T; Ueno S
    J Mol Neurosci; 2005; 25(2):165-9. PubMed ID: 15784964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.
    Legleiter J; Mitchell E; Lotz GP; Sapp E; Ng C; DiFiglia M; Thompson LM; Muchowski PJ
    J Biol Chem; 2010 May; 285(19):14777-90. PubMed ID: 20220138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
    Preisinger E; Jordan BM; Kazantsev A; Housman D
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains.
    Robertson AL; Bate MA; Buckle AM; Bottomley SP
    J Mol Biol; 2011 Nov; 413(4):879-87. PubMed ID: 21945530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
    Kubota H; Kitamura A; Nagata K
    Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism.
    Thakur AK; Jayaraman M; Mishra R; Thakur M; Chellgren VM; Byeon IJ; Anjum DH; Kodali R; Creamer TP; Conway JF; Gronenborn AM; Wetzel R
    Nat Struct Mol Biol; 2009 Apr; 16(4):380-9. PubMed ID: 19270701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models.
    Hong H; Koon AC; Chen ZS; Wei Y; An Y; Li W; Lau MHY; Lau KF; Ngo JCK; Wong CH; Au-Yeung HY; Zimmerman SC; Chan HYE
    J Biol Chem; 2019 Feb; 294(8):2757-2770. PubMed ID: 30593503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
    Minakawa EN; Nagai Y
    Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein.
    Scarafone N; Pain C; Fratamico A; Gaspard G; Yilmaz N; Filée P; Galleni M; Matagne A; Dumoulin M
    PLoS One; 2012; 7(3):e31253. PubMed ID: 22438863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments.
    Jayaraman M; Kodali R; Sahoo B; Thakur AK; Mayasundari A; Mishra R; Peterson CB; Wetzel R
    J Mol Biol; 2012 Feb; 415(5):881-99. PubMed ID: 22178474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DNAJB6 and DNAJB8 protein chaperones prevent intracellular aggregation of polyglutamine peptides.
    Gillis J; Schipper-Krom S; Juenemann K; Gruber A; Coolen S; van den Nieuwendijk R; van Veen H; Overkleeft H; Goedhart J; Kampinga HH; Reits EA
    J Biol Chem; 2013 Jun; 288(24):17225-37. PubMed ID: 23612975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones.
    Vos MJ; Zijlstra MP; Kanon B; van Waarde-Verhagen MA; Brunt ER; Oosterveld-Hut HM; Carra S; Sibon OC; Kampinga HH
    Hum Mol Genet; 2010 Dec; 19(23):4677-93. PubMed ID: 20843828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.